Medical Licensing (MD/DO) · Independent exam preparation
ABMGG General Examination Study Guide
Practise inheritance calculations, genetic test selection, variant interpretation, and screening decisions across the ABMGG General Examination's 11 domains.
By CertMedbry · Updated 15 October 2026
Calculate family risks, distinguish screening from diagnosis, select informative genetic tests, and evaluate variant evidence. This selective 60-concept guide follows the ABMGG General Examination blueprint effective August 2025, with greatest emphasis on single gene inheritance and genomics. The complete official content outline defines the full examination scope, including disorder groups and methods beyond these selected lessons.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and certification pathway does this guide cover?
The ABMGG General Examination within initial specialty certification. ABMGG publishes separate specialty outlines for Clinical Genetics and Genomics, Medical/Clinical Biochemical Genetics, and Laboratory Genetics and Genomics. This guide covers their shared general paper, without combining their specialty examinations or treating it as a medical licensure examination.
ABMGG: Content Outlines and Blueprints · ABMGG: Testing Process
Why does the examination name identify ABMGG rather than ACMG?
ABMGG is the certifying board. ACMG is the American College of Medical Genetics and Genomics, a professional college that identifies ABMGG as the board-certification organization.
How many questions are on the General Examination, and how many are scored?
The General Examination contains 100 items, divided into two blocks of 50. The scored-versus-pretest breakdown is not specified in the cited examination instructions. Specialty examinations contain 150 items and are separate examinations.
ABMGG: Testing Process · Bulletin-of-Information-2026-New-Deadlines-Update.pdf
What are the duration, delivery method, and question format?
The General Examination is computer-based at Pearson VUE testing centers and uses single-best-answer multiple-choice questions. Each 50-item block allows 60 minutes, with a 10-minute break between blocks. Completed blocks cannot be revisited. Testing time totals 120 minutes; the 2026 Bulletin describes approximately 2.5 hours including the tutorial and breaks. Adaptive delivery is not established by these instructions.
ABMGG: Testing Process · Bulletin-of-Information-2026-New-Deadlines-Update.pdf
Which blueprint and effective dates apply to this guide?
This guide uses the General Exam: Blueprint and Content Codes effective August 2025. ABMGG lists this outline for the 2026 examination and specifies ISCN 2024 for cytogenomic nomenclature on those examinations. ABMGG has announced examinations for August 11–14, 2027; candidates should confirm the outline and instructions applicable to their intended cycle.
ABMGG General Exam: Blueprint and Content Codes · ABMGG: Content Outlines and Blueprints · ABMGG official homepage
How are the official domains weighted?
Approximate allocations are: Chromosomal basis of inheritance 4%; Chromosome and gene structure and function 6%; Population genetics 4%; Cytogenetics 8%; Single gene inheritance 36%; Gene environment interactions 6%; Reproductive Genetics 7%; Cancer genetics 8%; Population screening 4%; Genetic counseling 3%; Genomics 14%. The guide, questions, and cards emphasize the larger domains while retaining every domain; small collections cannot reproduce these percentages exactly.
How does this general paper relate to specialty examinations and continuing certification?
Initial candidates must pass the General Examination and at least one applicable specialty examination to achieve diplomate status. They need not pass both in the same year. Existing ABMGG diplomates adding a specialty do not retake the General Examination. CertLink continuing certification is a separate activity.
ABMGG: Testing Process · Bulletin-of-Information-2026-New-Deadlines-Update.pdf · ABMGG official homepage
ABMGG awards the relevant specialty board certifications; ACMG is the professional college. This independent guide covers the shared General Examination for initial certification. Passing this paper alone does not confer certification: initial candidates must also pass an applicable specialty examination.
Outline used: ABMGG General Exam: Blueprint and Content Codes, effective August 2025; current published outline checked on 2026-10-09. The workbook label 'American College of Medical Genetics and Genomics (ACMG) Board Certification' inaccurately identifies the professional college as the certifying board. This preview maps that umbrella label to ABMGG's General Examination while preserving the assigned slug. Initial certification also requires the applicable specialty examination; this preview covers only the general paper.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Chromosomal basis of inheritance4%
1.How do the two meiotic divisions separate chromosomes?
Meiosis reduces a diploid precursor to haploid gametes through one DNA replication followed by two divisions. Homologous chromosomes separate during meiosis I, whereas sister chromatids separate during meiosis II. A chromosome remains duplicated after the first division even though its homolog has moved to the other daughter cell. Distinguishing homolog separation from chromatid separation explains why chromosome number and DNA content do not change in identical ways throughout gametogenesis.
Apply it
A diagram shows paired maternal and paternal homologs moving to opposite poles while each chromosome retains two chromatids. Identify meiosis I, then predict that another division must separate sister chromatids before gamete formation is complete.
Common pitfall: Counting chromatids as separate chromosomes before centromeres divide can falsely suggest that meiosis I has failed to reduce the chromosome complement.
2.Why does crossing over create new allele combinations?
Crossing over exchanges corresponding DNA segments between nonsister chromatids of homologous chromosomes during meiosis. It can separate alleles that were originally inherited together, producing recombinant gametes without normally changing the total amount of genetic material. The informative clue is a new combination of linked markers rather than a gain or loss of a chromosome. Recombination therefore changes the relationship among alleles while preserving their chromosomal context.
Apply it
A parent has marker haplotypes A–B and a–b. A gamete carrying A–b can arise through crossing over between the markers. Explain why this observation does not require a new mutation at either marker.
Common pitfall: Ordinary homologous crossing over should not be equated with deletion or duplication; unequal alignment is a different mechanism with different dosage consequences.
Chromosome and gene structure and function6%
3.When does a coding insertion shift the reading frame?
Protein-coding sequence is translated in successive three-nucleotide codons. An insertion or deletion whose length is not divisible by three changes the downstream grouping of nucleotides and can introduce a premature stop. A three-nucleotide change usually preserves the reading frame while adding or removing an amino acid. This distinction describes sequence consequences; it does not independently establish disease causation because location, transcript relevance, and the gene's disease mechanism still matter.
Apply it
Two coding variants insert two and three nucleotides, respectively. Predict a frameshift for the two-nucleotide insertion and an in-frame insertion for the three-nucleotide change, then identify the need to assess each altered protein's function.
Common pitfall: An in-frame change is not automatically benign, and a frameshift is not automatically pathogenic when the affected transcript or disease mechanism is irrelevant.
MedlinePlus Genetics: What kinds of gene variants are possible? · Richards et al.: ACMG/AMP Standards and Guidelines for the Interpretation of Sequence Variants
4.How can abnormal splicing alter a protein?
Splicing removes introns and joins exons in a precursor RNA transcript. A sequence change that disrupts this process can cause exon skipping, intron retention, or use of an alternative splice site. The resulting transcript may lose coding sequence or acquire a frameshift. RNA analysis can demonstrate the actual transcript consequence, whereas a DNA-based prediction alone estimates that consequence. Tissue expression and naturally occurring transcript isoforms affect interpretation of any observed RNA product.
Apply it
A variant near an exon boundary is predicted to disrupt splicing. Patient RNA shows a shorter transcript lacking that exon. Determine whether the skipped exon preserves the reading frame before inferring the likely protein consequence.
Common pitfall: An abnormal band alone does not establish pathogenicity; the transcript must be relevant, and the assay must distinguish disease-associated changes from normal alternative splicing.
Richards et al.: ACMG/AMP Standards and Guidelines for the Interpretation of Sequence Variants
5.How can methylation change expression without changing sequence?
Epigenetic regulation changes gene activity without requiring a change in the underlying nucleotide sequence. At imprinted regions, methylation patterns help distinguish parental copies and regulate which copy is expressed. A person can therefore have two structurally present copies yet lack the expected active contribution. Sequence analysis, copy-number analysis, and methylation analysis answer different questions, so a normal sequence result cannot exclude every mechanism that disrupts parent-specific gene expression.
Apply it
A patient has an imprinting-disorder phenotype and two detectable copies of the relevant region. Consider a methylation study to assess the parental expression pattern rather than concluding that normal copy number excludes an imprinting defect.
Common pitfall: Methylation abnormalities can arise through several mechanisms; an abnormal pattern does not, by itself, identify whether deletion, uniparental disomy, or another defect caused it.
MedlinePlus Genetics: Genomic imprinting and uniparental disomy
6.Why do some X-linked genes escape dosage silencing?
In cells with two X chromosomes, one X is largely inactivated early in development, reducing expression from many genes on that chromosome. Inactivation is incomplete: some genes escape and remain expressed from both copies. Consequently, X-chromosome dosage cannot be understood by assuming that an entire extra X contributes no expression. The relevant distinction is between genes subject to inactivation and genes that escape, rather than simply counting visibly active X chromosomes.
Apply it
A learner argues that an additional X chromosome must be phenotypically irrelevant because only one X remains active. Explain how expression from escape genes undermines that conclusion even when most genes undergo dosage compensation.
Common pitfall: The phrase inactive X is shorthand for broad silencing; treating it as complete transcriptional absence overlooks escape genes and their possible dosage effects.
Population genetics4%
7.How do Hardy–Weinberg frequencies estimate carrier prevalence?
For two alleles with frequencies p and q, p + q = 1. Under Hardy–Weinberg assumptions, genotype frequencies are p², 2pq, and q². If a fully penetrant autosomal recessive disorder is represented by the recessive homozygote, its prevalence estimates q² and the heterozygote frequency is 2pq. The calculation depends on the population model, including random mating and absence of important forces or structure that distort the assumed genotype distribution.
Apply it
In a hypothetical equilibrium population, recessive disease prevalence is 1 in 10,000. Calculate q = 0.01 and p = 0.99, giving a carrier frequency of 0.0198, approximately 1 in 51 people in that population.
Common pitfall: Using disease prevalence directly as the allele frequency confuses q² with q; applying one population's estimate to a different ancestry can also mislead.
CDC Stacks: Supplementary Material—Hardy-Weinberg Equilibrium
8.Why can a founder population have unusual allele frequencies?
Genetic drift changes allele frequencies through chance rather than because an allele necessarily improves survival or reproduction. A small founding group can carry a sample of alleles that differs from the original population, and subsequent drift can preserve or amplify those differences. An unexpectedly frequent pathogenic allele in an isolate can therefore reflect population history. Frequency interpretation should consider the relevant population rather than assuming that a pooled global estimate describes every subgroup.
Apply it
A rare recessive allele is relatively frequent in a small community descended from a few founders. Explain how chance sampling and drift can account for the pattern without proposing that the disease confers a survival advantage.
Common pitfall: A high local frequency does not prove positive selection, and a low overall frequency can conceal a much higher frequency within a founder population.
Cytogenetics8%
9.How does aneuploidy differ from a structural rearrangement?
Aneuploidy is a gain or loss of individual chromosomes, whereas structural rearrangements alter chromosome segments through events such as deletion, duplication, inversion, or translocation. These categories describe different abnormalities and may require different ways of characterizing them. A chromosome count can reveal an extra chromosome but does not fully describe whether material is rearranged. Conversely, a structurally abnormal chromosome may be present in a cell with an otherwise ordinary total chromosome count.
Apply it
One specimen contains 47 chromosomes with an additional chromosome 21; another contains 46 chromosomes with a segment transferred between two chromosomes. Classify the first finding as aneuploidy and investigate structural balance in the second.
Common pitfall: A total of 46 chromosomes does not establish a normal genome; clinically important deletions, duplications, and rearrangements can occur with an unchanged chromosome count.
MedlinePlus Genetics: Changes in chromosome number · MedlinePlus Genetics: Changes in chromosome structure
10.Why can mosaicism differ among tested tissues?
Chromosomal mosaicism means that an individual has cell populations with different chromosome complements. A postzygotic division error can generate an abnormal lineage whose distribution depends on when the event occurred and which descendants populate particular tissues. The proportion measured in blood therefore describes that specimen rather than every organ. When the phenotype and laboratory result disagree, tissue representation and assay sensitivity are important explanations to consider before excluding a mosaic chromosome abnormality.
Apply it
A child has findings suggesting mosaic chromosome disease, but blood testing is unrevealing. Explain why a clinically selected alternative tissue might be informative if the abnormal lineage is absent or uncommon in circulating blood cells.
Common pitfall: A percentage of abnormal cells from one specimen is not a direct measurement of the percentage in the brain, skin, or entire body.
11.Which test can reveal a balanced chromosome exchange?
A balanced reciprocal translocation exchanges material without a detectable net gain or loss at the level being assessed. Karyotyping can show large-scale changes in chromosome arrangement, whereas a copy-number microarray primarily measures dosage and generally cannot identify a truly balanced exchange. The clinical question determines the useful method: assessing chromosome architecture differs from searching for small deletions or duplications. Apparent balance also does not guarantee that no gene or regulatory region has been disrupted.
Apply it
A healthy parent of children with different unbalanced chromosome complements has a normal microarray. Select chromosome analysis to evaluate a possible balanced parental rearrangement that could explain unbalanced segregation in the offspring.
Common pitfall: Normal microarray dosage does not establish normal chromosome architecture, and the term balanced should not be interpreted as proof that every breakpoint is harmless.
Miller et al.: Consensus statement on chromosomal microarray · MedlinePlus Genetics: Changes in chromosome structure
12.When is a targeted FISH study informative?
Fluorescence in situ hybridization uses labeled probes that bind complementary DNA sequences, allowing selected loci or chromosome regions to be visualized. Its strength is answering a defined question about the probe targets, such as their presence, number, or location. Its scope is limited by probe design: a normal targeted result does not survey all chromosome regions. Interpretation therefore begins with the precise genomic target rather than treating FISH as a general genome-wide exclusion test.
Apply it
A laboratory uses a probe for one suspected deleted region and observes the expected signals. Explain that the targeted deletion is not demonstrated, while deletions elsewhere and sequence variants remain outside that particular assay's scope.
Common pitfall: More fluorescent signals do not automatically identify a mechanism; probe location, chromosome context, and the intended assay design determine what the signal pattern means.
13.What does a copy-number microarray result establish?
Chromosomal microarrays detect genomic dosage differences at interrogated regions, making them useful for identifying deletions and duplications that may be too small for routine chromosome visualization. A detected imbalance is a laboratory observation whose clinical significance requires interpretation. A normal result does not exclude sequence-level variants or truly balanced rearrangements. The 2010 microarray consensus supports these methodological distinctions; it should not be treated as a universal current testing recommendation for every clinical presentation.
Apply it
A patient has a confirmed submicroscopic deletion, while a relative with a related phenotype has normal microarray dosage. Explain why the relative could still have a sequence variant or another mechanism outside copy-number detection.
Common pitfall: Detecting a dosage change does not automatically prove that it explains the phenotype; genomic content, inheritance, and established disease associations still affect interpretation.
Miller et al.: Consensus statement on chromosomal microarray
Single gene inheritance36%
14.How is autosomal dominant transmission risk calculated?
For a heterozygous parent with an autosomal dominant pathogenic variant and a partner without that variant, each child has a one-half chance of inheriting the variant. This transmission probability is distinct from the chance of manifesting disease, which can depend on penetrance and age. Each conception is a new segregation event. A previous affected or unaffected child does not change the next child's transmission probability under the stated Mendelian model.
Apply it
A heterozygous parent has three children who did not inherit the familial variant. For a fourth pregnancy, retain a 50% transmission probability rather than increasing it to compensate for the earlier outcomes.
Common pitfall: A dominant pedigree does not mean every carrier is clinically recognizable; reduced penetrance can hide transmission through an apparently unaffected parent or relative.
MedlinePlus Genetics: Chances of inheriting a genetic condition · MedlinePlus Genetics: Reduced penetrance and variable expressivity
15.How do two recessive carriers create an affected-child risk?
When both parents carry a pathogenic variant for the same autosomal recessive condition, each transmits either their affected allele or their other allele with equal probability. The combinations yield one-quarter affected children, one-half heterozygous carriers, and one-quarter children with neither familial variant, assuming the variants cause disease when paired. The crucial prerequisite is a compatible recessive mechanism in the same gene; carrying unrelated recessive conditions does not create this particular one-quarter risk.
Apply it
Each partner carries a different established pathogenic HEXA variant. Construct the four equally likely parental allele combinations and identify the combination inheriting both variants as the affected genotype, assuming the stated recessive disease mechanism.
Common pitfall: Different pathogenic variants can cause the same recessive disorder when inherited together; matching the exact nucleotide change between parents is not required for risk.
MedlinePlus Genetics: Chances of inheriting a genetic condition · MedlinePlus Genetics: Tay-Sachs disease
16.Why is an unaffected recessive sibling's carrier risk two-thirds?
For two heterozygous parents, the Mendelian possibilities are one affected genotype, two carrier outcomes, and one noncarrier outcome. If a sibling is known to be unaffected in a fully penetrant condition with reliable age-appropriate assessment, the affected outcome is excluded. Two of the three remaining equally likely outcomes are carriers, giving a conditional probability of two-thirds. This updates risk using phenotype information rather than changing how either parent's alleles segregate.
Apply it
An unaffected adult has a sibling with a fully penetrant recessive disorder and two confirmed carrier parents. Before molecular testing, calculate a two-thirds carrier probability, provided the adult's unaffected status reliably excludes the disease genotype.
Common pitfall: The two-thirds result requires a valid exclusion of the affected genotype; late onset, reduced penetrance, or uncertain diagnosis can invalidate that conditioning step.
MedlinePlus Genetics: Chances of inheriting a genetic condition
17.Why do MYH7 cardiomyopathy and CFTR-related disease require different variant reasoning?
The 2015 ACMG/AMP guidance contrasts dominant MYH7-related hypertrophic cardiomyopathy with recessive CFTR-related cystic fibrosis. A newly observed MYH7 nonsense variant cannot be declared causative for dominant hypertrophic cardiomyopathy merely because it truncates the protein. Loss of function is an established mechanism for recessive CFTR disease, where the second allele and phase also matter. The clinical comparison connects cardiac versus multisystem disease, dominant versus recessive inheritance, and the specific molecular effect required by each gene–disease relationship.
Apply it
For a cardiomyopathy case, assess the MYH7 variant's established disease mechanism and family segregation. For a recessive CFTR hypothesis, determine whether two disease-causing alleles affect opposite homologs. The same variant class does not supply the same diagnostic argument in both cases.
Common pitfall: Predicted protein truncation is a sequence consequence. Applying a loss-of-function pathogenicity criterion requires a supported loss-of-function disease mechanism.
Richards et al.: ACMG/AMP Standards and Guidelines for the Interpretation of Sequence Variants
18.How does X-linked recessive risk depend on the child's sex?
For a heterozygous mother and a father without the familial X-linked recessive variant, each son has a one-half chance of inheriting the variant-bearing X. Each daughter also has a one-half chance of inheriting that maternal X, usually producing heterozygosity rather than the same risk model used for hemizygous sons. A father transmits his X chromosome to daughters and his Y to sons, so father-to-son transmission does not follow this X-linked mechanism.
Apply it
A carrier mother asks about a son whose sex is already known. Use a 50% variant-inheritance probability for that son; do not multiply by another one-half probability for being male after sex has been established.
Common pitfall: A risk conditional on a known son differs from the chance of an affected son among all pregnancies; the denominator must match the question.
MedlinePlus Genetics: Inheritance patterns · MedlinePlus Genetics: Chances of inheriting a genetic condition
19.What transmission pattern suggests X-linked dominant inheritance?
An affected father transmits his X chromosome to every daughter and to no sons. For an X-linked dominant disorder, this creates a characteristic paternal pattern, assuming the variant is compatible with survival and penetrance is accounted for. A heterozygous mother can transmit the variant to children of either sex with one-half probability. The transmission route identifies the chromosome involved; differences in clinical expression between sexes require additional disease-specific explanation.
Apply it
A father has a confirmed X-linked dominant variant, and the mother lacks it. Predict variant inheritance in all daughters and no sons, then separate this transmission prediction from assumptions about the severity of their manifestations.
Common pitfall: Absence of father-to-son transmission supports an X-linked model but does not alone prove it; small families and chance can produce similar-looking pedigrees.
MedlinePlus Genetics: Inheritance patterns · MedlinePlus Genetics: Chances of inheriting a genetic condition
20.How can X-inactivation modify a heterozygous phenotype?
A heterozygous individual with two X chromosomes contains cell populations expressing different parental X chromosomes. If the proportions are skewed, more cells in a relevant tissue may express the X bearing a pathogenic variant. This can help explain why some heterozygotes develop manifestations of an X-linked condition. Interpretation remains tissue-dependent, and not all genes undergo inactivation. An inactivation measurement from one tissue is therefore not a complete explanation of every clinical finding.
Apply it
Two heterozygous relatives have different manifestations of an X-linked condition. Consider differences in relevant tissue-level X-inactivation as one modifier, while recognizing that a blood assay may not represent the affected organ's cellular pattern.
Common pitfall: Calling every heterozygote an asymptomatic carrier ignores cellular mosaicism; conversely, a skewed blood result does not independently prove the cause of a symptom.
MedlinePlus Genetics: X chromosome · MedlinePlus Genetics: Glucose-6-phosphate dehydrogenase deficiency
21.How do maternal inheritance and heteroplasmy explain mitochondrial DNA disease?
Mitochondrial DNA is ordinarily maternally inherited. Heteroplasmy is the coexistence of different mitochondrial DNA populations, such as reference and pathogenic sequences, within an individual or cell. Their proportions can differ among tissues and among a mother's offspring because mitochondrial genomes are distributed unevenly during reproduction and cell division. These differences help explain variable expression within a maternal family. The measured variant proportion describes the tested specimen and does not provide a universal prediction of another tissue's function or an offspring's severity.
Apply it
Maternal relatives have different manifestations, and a low variant proportion is measured in blood. Consider whether blood adequately represents the affected tissue and whether another appropriate specimen could be more informative. Do not apply a universal 50% or 25% transmission fraction to a heteroplasmic mitochondrial DNA variant.
Common pitfall: Maternal transmission does not imply identical variant proportions or severity in every child. Disorders of mitochondrial function caused by nuclear genes follow their own inheritance patterns.
MedlinePlus Genetics: Inheritance patterns · ABMGG General Exam: Blueprint and Content Codes
22.How does penetrance change phenotype risk after transmission?
Penetrance is the proportion of people with a particular genotype who show its associated phenotype. Reduced penetrance means that some carriers remain clinically unaffected despite carrying the disease-associated variant. When assumptions are explicit, phenotype probability can be calculated by multiplying transmission probability by penetrance. Age and the definition of the phenotype matter: a lifetime penetrance estimate should not be substituted for the probability of showing disease in childhood or at a particular examination.
Apply it
In a hypothetical model, a heterozygous parent transmits a variant with 50% probability and carriers have 80% penetrance by a specified age. Calculate a 40% probability of the child's phenotype by that age.
Common pitfall: An unaffected parent does not exclude a dominant variant, and an 80% penetrance estimate does not mean each carrier is 80% clinically affected.
MedlinePlus Genetics: Reduced penetrance and variable expressivity · MedlinePlus Genetics: Chances of inheriting a genetic condition
23.How does variable expressivity differ from reduced penetrance?
Variable expressivity describes differences in the features or severity of a condition among people who manifest it. Reduced penetrance describes whether the associated phenotype appears at all. These properties can coexist but answer different questions. If several carriers all show manifestations but differ in organ involvement or severity, expressivity is the discriminating concept. If an adequately assessed carrier has no manifestations, penetrance becomes relevant rather than merely labeling the disease mild.
Apply it
Three relatives with the same pathogenic variant all have recognizable disease, but one has isolated skeletal findings and another has additional cardiac involvement. Identify variable expressivity while avoiding a claim that different severity changes variant-transmission probability.
Common pitfall: A mild phenotype still counts as expression when it meets the phenotype definition; severity differences alone do not demonstrate incomplete penetrance in a family.
MedlinePlus Genetics: Reduced penetrance and variable expressivity
24.How do different FGFR3 substitutions distinguish skeletal dysplasia phenotypes?
Allelic heterogeneity means that different variants in one gene can produce disease; the exact substitution can also distinguish related phenotypes. The 2015 ACMG/AMP guidance contrasts FGFR3 p.Lys650Asn or p.Lys650Gln in relatively mild hypochondroplasia with p.Lys650Glu in thanatophoric dysplasia type 2, a lethal skeletal dysplasia. These dominant FGFR3-related conditions demonstrate why a shared gene or affected residue does not establish an identical phenotype. Molecular interpretation must retain the precise amino acid change.
Apply it
For two patients with markedly different skeletal severity, compare skeletal findings and the exact FGFR3 substitution. A previously established pathogenic change at the same residue can inform interpretation, but it does not establish that a new substitution causes the same disorder.
Common pitfall: A negative test for one recurrent variant does not exclude other pathogenic alleles. Conversely, different substitutions at one residue should not automatically receive the same phenotype assignment.
NHGRI: Genetic Testing Report—Glossary · Richards et al.: ACMG/AMP Standards and Guidelines for the Interpretation of Sequence Variants
25.How does locus heterogeneity change the investigation of hearing loss?
Locus heterogeneity means that different genes can cause overlapping phenotypes. Hearing loss illustrates why a clinical category may not identify one causal locus or inheritance pattern. GJB2-associated recessive hearing loss requires a compatible biallelic explanation; other hearing-loss diagnoses can have different transmission mechanisms. A relevant multigene analysis can investigate several established causes, but the interpretation must still evaluate each gene's inheritance, variant mechanism, and phenotype fit.
Apply it
After testing one hearing-loss gene is negative, review whether the proposed assay evaluates other relevant genes and variant classes. If two candidate recessive variants are identified, establish their classification and phase before assigning a diagnosis.
Common pitfall: Similar hearing phenotypes do not establish identical recurrence risks. One negative gene result does not exclude all monogenic hearing loss.
NHGRI: Genetic Testing Report—Glossary · MedlinePlus Genetics: Whole exome and whole genome sequencing · Richards et al.: ACMG/AMP Standards and Guidelines for the Interpretation of Sequence Variants
26.How does Marfan syndrome connect skeletal findings with cardiovascular disease?
Marfan syndrome is an autosomal dominant disorder commonly associated with FBN1 variants. Its combination of skeletal and cardiovascular manifestations illustrates pleiotropy: one gene-related disorder affects several organ systems. A tall, slender build with long fingers can coexist with serious heart and blood-vessel complications. Differences in manifestations among affected relatives illustrate variable expressivity. The family's mild skeletal presentation therefore cannot reliably predict another relative's cardiovascular involvement.
Apply it
Compare a relative with mild skeletal manifestations with another who has cardiovascular complications. Evaluate cardiovascular findings directly and assess the familial molecular diagnosis rather than assuming that skeletal appearance predicts internal involvement.
Common pitfall: Tall stature alone does not establish Marfan syndrome. Pleiotropy describes multiple effects of one disorder; locus heterogeneity describes overlapping phenotypes caused by different genes.
MedlinePlus Genetics: Reduced penetrance and variable expressivity · MedlinePlus Genetics: Inheritance patterns
27.Why can the parental origin of an allele matter?
Genomic imprinting causes certain genes to be expressed differently according to whether they were inherited from the mother or father. If one parental copy is normally silenced, loss or disruption of the active contribution can cause disease even when another copy is physically present. Parent of origin is therefore mechanistically important at imprinted loci. This differs from ordinary autosomal inheritance, where the same pathogenic allele generally does not change significance simply because a different parent transmitted it.
Apply it
A hypothetical imprinted gene is expressed only from the paternal copy. A child loses the paternal contribution but retains a maternal copy. Explain why retaining one physical copy does not restore the missing active expression.
Common pitfall: Imprinting is locus-specific; do not assume every gene on a chromosome is silenced according to the same parental pattern or follows identical clinical rules.
MedlinePlus Genetics: Genomic imprinting and uniparental disomy
28.How can uniparental disomy cause disease without a deletion?
Uniparental disomy means that both copies of a chromosome or chromosome segment originate from one parent. Disease can result from abnormal parent-of-origin expression at imprinted loci. If two copies of the same parental homolog are present, a recessive pathogenic allele carried by that parent can also become homozygous. These are distinct mechanisms: an imprinting effect depends on parental origin, whereas recessive unmasking depends on the inherited allele content and whether relevant regions are isodisomic.
Apply it
A child has two copies of a chromosome, both derived from the mother, and an imprinting phenotype. Explain why normal dosage does not exclude disease, then consider whether isodisomic regions could additionally uncover a maternal recessive allele.
Common pitfall: Uniparental disomy is not always clinically abnormal; consequences depend on imprinted regions and allele content, and heterodisomy does not automatically create recessive homozygosity.
MedlinePlus Genetics: Genomic imprinting and uniparental disomy
29.When does anticipation suggest an unstable repeat expansion?
Anticipation is a pattern in which a condition appears at an earlier age or with greater severity in successive generations. In some disorders, expansion of an unstable repeated DNA sequence during transmission explains that pattern. The relevant clue is an intergenerational change linked to repeat size, rather than ordinary variability among relatives. Repeat-associated disorders require attention to the specific condition because expansion behavior, parental effects, and the relationship between repeat size and manifestations are not uniform.
Apply it
A family shows progressively earlier onset across generations, and a repeat assay documents increasing repeat length. Link these observations through dynamic mutation rather than attributing the pattern solely to ordinary dominant transmission.
Common pitfall: Earlier diagnosis in younger generations can mimic anticipation through improved recognition; the pedigree pattern alone does not establish a repeat-expansion mechanism without supporting evidence.
30.Why can an apparently new variant recur in siblings?
Germline mosaicism occurs when a pathogenic variant is present in some of a parent's egg or sperm cells, even if it is absent from the tested blood sample. A child can therefore have an apparently de novo variant that recurs in another pregnancy. Negative parental blood testing lowers support for a detectable constitutional variant but does not directly assay every germ cell. Recurrence counseling must distinguish this biological possibility from the usual transmission risk of a confirmed heterozygous parent.
Apply it
Two siblings share the same pathogenic variant, while routine parental blood tests are negative. Consider parental germline mosaicism as an explanation instead of concluding that two identical independent mutations must have occurred.
Common pitfall: Negative blood testing does not justify a universal zero recurrence risk, and germline mosaicism does not justify assigning every family a standard 50% risk.
31.How does a postzygotic variant create somatic mosaicism?
A variant arising after fertilization can be inherited by only a subset of descendant cells, creating somatic mosaicism. Its distribution depends on developmental timing and cell lineage. A localized or asymmetric phenotype can therefore reflect a pathogenic variant confined to affected tissue, while blood analysis remains negative. Transmission implications depend on whether germ cells are involved; a variant's presence in skin alone does not establish that it is present in eggs or sperm.
Apply it
A person has a segmental phenotype, and sequencing detects a pathogenic variant in affected skin but not blood. Interpret the results as tissue-limited evidence of mosaicism and keep germline involvement as a separate question.
Common pitfall: The fraction of variant reads in one tissue does not directly equal the fraction of affected cells throughout the body or the probability of transmission.
32.How does HEXA deficiency cause Tay–Sachs disease?
HEXA encodes a component of beta-hexosaminidase A, an enzyme needed to break down GM2 ganglioside. Disease-associated deficiency allows GM2 to accumulate in lysosomes, particularly in nerve cells, producing progressive neurologic dysfunction. Tay–Sachs disease follows autosomal recessive inheritance. Little or no residual enzyme activity is associated with severe early disease, whereas residual activity can be associated with later-onset forms. A shared gene diagnosis therefore does not establish an identical clinical course.
Apply it
A child with progressive neurologic regression has markedly reduced hexosaminidase A activity and two pathogenic HEXA variants. Explain the findings through impaired GM2 degradation and lysosomal accumulation rather than a primary chromosome-number abnormality.
Common pitfall: An isolated heterozygous HEXA result does not establish an affected genotype; the biochemical and molecular findings must be interpreted within the recessive disease model.
33.How can developmental pattern distinguish a syndromic disorder from neurodegeneration?
Congenital patterning abnormalities and progressive loss of acquired skills direct different diagnostic arguments. Distinctive facial features, hirsutism, and upper-limb defects support consideration of NIPBL-related Cornelia de Lange syndrome; a concordant de novo finding can strengthen a dominant molecular explanation. Progressive regression with deficient hexosaminidase A instead supports the recessive lysosomal mechanism of Tay–Sachs disease. Developmental delay alone is less specific than either a recognizable malformation pattern or a demonstrated biochemical defect.
Apply it
Compare a child with congenital upper-limb abnormalities and a concordant NIPBL variant with a child who loses acquired motor skills and has markedly reduced hexosaminidase A. Use parental testing for the first molecular hypothesis and biochemical testing with biallelic HEXA assessment for the second.
Common pitfall: A rare variant plus nonspecific developmental delay provides weaker phenotype support than a characteristic syndrome. Regression should not be treated as interchangeable with static developmental delay.
Richards et al.: ACMG/AMP Standards and Guidelines for the Interpretation of Sequence Variants · MedlinePlus Genetics: Tay-Sachs disease
34.Why does phase matter for two recessive variants?
Two variants in one recessive disease gene may be in trans, with one on each homolog, or in cis, together on one homolog. A typical biallelic recessive explanation requires pathogenic changes affecting both gene copies, so merely counting two variants is insufficient. Parental or other appropriate phasing studies can establish their arrangement. Classification also matters: two variants in trans do not prove disease when one or both lack adequate evidence of pathogenicity.
Apply it
A child has two candidate variants in a recessive gene. One is inherited from the mother and the other from the father. Establish trans phase, then separately assess whether both variants and the phenotype support the proposed diagnosis.
Common pitfall: Two variants inherited together from one parent may leave the other homolog intact; variant count is not a substitute for phase or pathogenicity assessment.
Richards et al.: ACMG/AMP Standards and Guidelines for the Interpretation of Sequence Variants
35.How does a dominant-negative effect differ from simple loss?
A dominant-negative variant produces an altered product that interferes with the function of the normal product, rather than merely reducing the amount of protein made. By contrast, haploinsufficiency occurs when one functional copy does not provide enough activity. Both can produce dominant inheritance, but their molecular predictions differ. Variant interpretation therefore requires knowing which mechanism is established for the disorder; a change that abolishes production need not mimic a change that creates an interfering protein.
Apply it
In a hypothetical multimeric protein disorder, a missense product disrupts complexes containing normal subunits, while complete absence of the altered product does not. Identify interference as the mechanism rather than assuming that all reduced-function variants behave alike.
Common pitfall: Dominant inheritance describes family transmission, not a single protein mechanism; gain of function, haploinsufficiency, and dominant-negative effects cannot be substituted for one another.
Richards et al.: ACMG/AMP Standards and Guidelines for the Interpretation of Sequence Variants
Gene environment interactions6%
36.What does heritability measure in a population?
Heritability describes the proportion of variation in a trait within a particular population and environment that is associated with genetic differences. It does not describe what fraction of an individual's trait was caused by genes. Estimates can change when the population or environmental variation changes. A highly heritable trait can still respond to environmental intervention because explaining existing variation and determining whether an exposure can alter outcomes are different questions.
Apply it
A hypothetical study estimates 70% heritability for a trait in one population. Explain that this concerns variation among those participants, not a claim that 70% of one patient's condition is genetic or environmentally unchangeable.
Common pitfall: Heritability is not penetrance, recurrence risk, or the probability that a person's condition was inherited; transferring the estimate across populations requires care.
37.Why do complex traits lack one universal Mendelian risk?
Multifactorial traits reflect contributions from multiple genetic differences and environmental factors rather than segregation of one sufficient allele. Their familial clustering does not automatically justify a one-quarter or one-half recurrence estimate. In a threshold model, underlying susceptibility is continuous while the observed condition appears after a threshold is crossed. The practical distinction is between a model-based or empiric population risk and a Mendelian transmission probability for a defined variant with a specified inheritance pattern.
Apply it
A family has several relatives with a common complex condition but no established monogenic diagnosis. Explain why assigning a 50% recurrence risk solely from vertical family clustering would confuse familial aggregation with autosomal dominant inheritance.
Common pitfall: The presence of affected relatives supports shared susceptibility but does not establish a single causal allele, complete penetrance, or a fixed Mendelian recurrence fraction.
MedlinePlus Genetics: Heritability · ABMGG General Exam: Blueprint and Content Codes
38.Why do exposures trigger hemolysis in G6PD deficiency?
G6PD helps protect red blood cells from oxidative damage. Deficiency reduces this protection, so infections, certain medicines, or fava beans can precipitate red-cell breakdown. The phenotype therefore depends on both genetic susceptibility and exposure, and an uneventful period without triggers does not establish normal enzyme function. This is a concrete gene–environment interaction: the same inherited vulnerability may have different clinical consequences under different oxidative stresses.
Apply it
A person with established G6PD deficiency develops jaundice and anemia after an oxidative trigger but had previously been well. Connect the episode to exposure-dependent red-cell vulnerability rather than rejecting the diagnosis because symptoms were intermittent.
Common pitfall: A trigger-associated episode is not evidence that the genetic defect was newly acquired; absence of symptoms between exposures does not remove the inherited susceptibility.
MedlinePlus Genetics: Glucose-6-phosphate dehydrogenase deficiency
39.Why should rasburicase be avoided in G6PD deficiency?
Rasburicase is a urate oxidase that converts uric acid to allantoin while generating hydrogen peroxide. G6PD supplies NADPH needed for red-cell protection against oxidative injury. In G6PD deficiency, rasburicase's peroxide production can therefore cause severe hemolysis and methemoglobinemia. The expanded CPIC guideline classifies rasburicase as high risk and recommends avoiding high-risk medicines in G6PD-deficient patients. This is susceptibility to the drug's oxidative consequences, rather than failure to metabolize rasburicase through G6PD.
Apply it
A patient with confirmed G6PD deficiency requires management of hyperuricemia during cancer treatment. Recognize rasburicase as a high-risk exposure to avoid. Evaluate other medicines using their own evidence and recommendations rather than assigning the same risk to an entire broad drug class.
Common pitfall: CPIC distinguishes high-, medium-, and low-to-no-risk exposures. A warning attached to one medicine does not establish equivalent risk for every chemically or therapeutically related medicine.
Reproductive Genetics7%
40.Why does negative carrier screening leave residual risk?
Carrier screening evaluates specified genes and variant classes rather than proving that a person carries no recessive disease alleles. Residual risk depends on the person's prior probability and what the assay can detect. A targeted test for one familial variant has a different scope from broader gene analysis. When one partner is a confirmed carrier, the other partner's negative result must therefore be interpreted using the actual test coverage rather than being converted into a zero affected-child risk.
Apply it
One partner carries an established recessive variant. The other tests negative only for that specific change. Explain that different pathogenic variants in the same gene remain possible and that the couple's residual risk has not been eliminated.
Common pitfall: A negative targeted test answers whether its target was detected; it does not establish comprehensive noncarrier status for every pathogenic allele or every recessive condition.
MedlinePlus Genetics: Interpreting genetic test results · NHGRI: Genetic Testing Report—Glossary
41.How does prevalence affect a positive prenatal screen?
Positive predictive value is the probability that a condition is present after a positive screening result. It depends on sensitivity, specificity, and the condition's prior probability in the screened population. Even highly specific cell-free DNA screening can produce false-positive results, especially for uncommon conditions. The 2025 SMFM guidance distinguishes screening from diagnosis and emphasizes counseling about predictive value. A positive screen should therefore be interpreted as revised probability rather than a definitive fetal chromosome diagnosis.
Apply it
Two hypothetical populations use the same assay but have different condition prevalences. Predict a lower positive predictive value in the lower-prevalence population, assuming identical sensitivity and specificity, rather than assuming assay performance makes prevalence irrelevant.
Common pitfall: Specificity is not the chance that a positive result is true; reversing those conditional probabilities can substantially overstate certainty after a screening result.
SMFM Consult Series #74: Cell-free DNA screening for aneuploidies—Updated guidance
42.How can placental mosaicism change prenatal diagnostic-test selection?
The pregnancy-derived component of maternal plasma cfDNA comes primarily from placental trophoblasts, and CVS also samples placental tissue. Confined placental mosaicism can therefore produce a positive screen without the same fetal chromosome finding. For monosomy X or trisomy 13 screening results with a normal first-trimester ultrasound, SMFM Consult Series #74's suggested-management table favors amniocentesis. Amniocentesis examines amniotic-fluid cells and helps resolve fetal status when placental findings are potentially discordant.
Apply it
After a monosomy X screen with normal first-trimester ultrasound, explain why amniocentesis is favored. CVS remains an option with counseling about placental mosaicism; mosaic CVS findings can require amniocentesis. The timing and ultrasound context should be included in the choice.
Common pitfall: Amniocentesis is not automatically required after every CVS result. SMFM specifies that certain definitive cultured CVS results can be diagnostic without follow-up amniocentesis.
SMFM Consult Series #74: Cell-free DNA screening for aneuploidies—Updated guidance
43.How do embryo aneuploidy and monogenic tests differ?
ACOG Committee Opinion 799 distinguishes PGT-M, which targets monogenic disease, from PGT-A, which screens embryos for chromosome aneuploidy. PGT-SR evaluates chromosome gains and losses associated with parental structural rearrangements. False-positive and false-negative results can occur with each modality. ACOG recommends offering prenatal aneuploidy screening or diagnostic testing after PGT-A, and emphasizes this offer after PGT-M or PGT-SR when concurrent PGT-A was not performed. Target-specific prenatal confirmation should also be discussed in relation to the preceding test.
Apply it
A couple with a familial pathogenic variant receives only a reassuring PGT-A result. Explain that this does not establish whether the embryo inherited that variant. After PGT-M, discuss prenatal confirmation of the familial finding and separately address aneuploidy screening or diagnosis.
Common pitfall: The phrase genetically tested embryo does not specify assay scope, and a negative PGT result does not guarantee a child without genetic abnormalities.
Cancer genetics8%
44.How does oncogenic activation promote abnormal growth?
An oncogene promotes cancer through excessive or inappropriate activity of a gene involved in cell growth or survival. Its normal counterpart, a proto-oncogene, participates in regulated cellular signaling. Activating alterations can increase the amount of its product or sustain activity when the usual growth stimulus is absent. The decisive mechanistic cue is increased growth-promoting function. This differs from loss of a tumor suppressor, which removes a normal restraint on proliferation. Finding a variant in a proto-oncogene does not by itself establish that the variant activates the protein.
Apply it
Compare two experimental findings: a signaling protein remains active after its normal stimulus is removed, whereas another protein loses its ability to restrain cell division. Persistent growth signaling supports oncogenic activation; loss of growth restraint supports a tumor-suppressor mechanism. Interpret the demonstrated functional effect rather than classifying both findings merely as cancer-associated mutations.
Common pitfall: Do not equate every sequence change in a proto-oncogene with oncogenic activation. A change may have no functional consequence or may reduce activity. Likewise, identifying an oncogenic alteration in tumor tissue does not by itself establish that the alteration is inherited.
NHGRI: Oncogene · NHGRI: Tumor Suppressor Gene · NCI: Genetic Testing for Inherited Cancer Risk
45.Why does loss of tumor-suppressor function promote cancer?
Tumor-suppressor genes encode products that restrain inappropriate growth or support protective processes such as DNA repair. Loss of their function can allow cells to accumulate damage or proliferate abnormally. This differs from an oncogene's excessive pro-growth activity. BRCA1 and BRCA2 illustrate inherited cancer susceptibility related to impaired DNA repair. A person's inherited predisposition and the additional changes occurring within a tumor are related levels of explanation rather than interchangeable laboratory findings.
Apply it
A hypothetical tumor loses the remaining functional copy of a gene whose product normally restrains cell division. Explain the result as loss of a protective function rather than activation of a protein that directly drives growth.
Common pitfall: A tumor-suppressor label does not establish the significance of every missense variant; evidence must show that the particular alteration affects the relevant protective function.
NHGRI: Tumor Suppressor Gene · NCI: BRCA Gene Changes—Cancer Risk and Genetic Testing
46.Why does a tumor BRCA finding not establish constitutional or inherited status?
A pathogenic BRCA variant found in a tumor can be constitutional or acquired during tumor development. Appropriate germline testing helps establish whether it is constitutional rather than restricted to the tumor. A constitutional variant can have been inherited or arisen de novo, so germline confirmation alone does not prove parental transmission. Parental testing and family assessment clarify which relatives could share the variant and how familial testing should proceed.
Apply it
A patient's tumor report identifies a pathogenic BRCA1 variant, and a sibling requests predictive testing. Establish the patient's constitutional status, then assess the family and parental findings before assigning the sibling a transmission-based risk.
Common pitfall: Pathogenic classification, constitutional status, and inheritance from a parent are different attributes. A tumor result alone establishes neither of the latter two.
NCI: BRCA Gene Changes—Cancer Risk and Genetic Testing · MedlinePlus Genetics: Gene variants and their origins
47.How does inherited cancer susceptibility differ from certainty?
An inherited pathogenic cancer-predisposition variant can increase risk without guaranteeing that cancer will develop. For dominant BRCA-associated susceptibility, a heterozygous parent can transmit the variant with one-half probability, but a child's lifetime cancer probability is a separate question. Risk estimates depend on the specific gene, cancer type, age, and other factors. Distinguishing transmission from penetrance prevents a Mendelian percentage from being mistaken for a universal probability of cancer.
Apply it
A parent with a germline pathogenic BRCA2 variant asks whether a child has a 50% chance of cancer. Clarify that 50% describes variant transmission; cancer risk requires separate, age- and gene-specific interpretation.
Common pitfall: An unaffected carrier does not disprove a cancer-predisposition diagnosis, and a negative family history does not automatically exclude an inherited pathogenic variant.
NCI: BRCA Gene Changes—Cancer Risk and Genetic Testing · MedlinePlus Genetics: Reduced penetrance and variable expressivity
48.How should a cancer-panel VUS affect management?
A variant of uncertain significance has insufficient or conflicting evidence to classify it as disease-causing or benign. NCI guidance states that a VUS should not ordinarily guide clinical decisions as though it were a pathogenic variant. Personal and family history remain important, and later reclassification may change interpretation. A VUS is therefore neither a confirmed explanation of familial cancer nor proof that inherited susceptibility has been excluded by the panel.
Apply it
A patient with a strong cancer family history receives only a BRCA VUS. Base risk assessment on established clinical and family evidence rather than treating the uncertain result as justification for a variant-directed preventive procedure.
Common pitfall: Uncertain does not mean probably pathogenic, and a VUS-only report should not be represented to relatives as a confirmed familial mutation for predictive testing.
Population screening4%
49.Why does an out-of-range newborn screen require prompt follow-up?
Newborn screening identifies infants who may have conditions for which timely evaluation matters; an out-of-range result is not itself a definitive diagnosis. HRSA emphasizes prompt follow-up and any additional testing recommended by the screening program or clinical team. An infant can appear well before disease manifestations develop, so appearance alone should not cancel follow-up. The immediate decision is to complete the indicated evaluation rather than labeling the child affected or dismissing the result.
Apply it
Parents report that their newborn looks healthy despite an out-of-range blood-spot result. Explain why they should promptly contact the designated care team and complete confirmatory evaluation instead of waiting for symptoms to appear.
Common pitfall: A repeat screening specimen may be requested in some situations, but families should follow the specific program instructions rather than inventing a delay or alternative pathway.
50.How do sensitivity and predictive value answer different questions?
Sensitivity asks what proportion of affected individuals screen positive. Positive predictive value asks what proportion of positive results represent truly affected individuals. Their denominators differ, so one cannot replace the other. In population screening, low prevalence can make false positives numerous relative to true positives even when sensitivity and specificity are high. A screening program therefore needs a clear confirmatory pathway and communication that preserves the distinction between increased probability and an established diagnosis.
Apply it
A hypothetical program finds 18 true positives and 82 false positives. Calculate a positive predictive value of 18%, then explain why this result alone does not reveal sensitivity without knowing the number of affected individuals missed.
Common pitfall: Dividing true positives by all affected people gives sensitivity, whereas dividing them by all positive tests gives predictive value; switching denominators changes the question.
SMFM Consult Series #74: Cell-free DNA screening for aneuploidies—Updated guidance
Genetic counseling3%
51.What makes genetic testing consent informed and voluntary?
Informed consent requires understanding the purpose of testing, its possible results, limitations, and relevant implications before choosing whether to proceed. Genetic results may affect medical decisions and family members, so discussion should include more than obtaining a signature. Voluntariness means that the person's decision is respected without coercion. A useful counseling approach checks understanding in the person's own words and addresses the specific concerns influencing the decision.
Apply it
An adult feels pressured by relatives to accept predictive testing. Explore the person's goals, explain possible outcomes and limitations, and confirm a voluntary choice rather than allowing family preference to substitute for the person's consent.
Common pitfall: A signed form does not demonstrate comprehension, and a clinician's belief that testing is beneficial does not remove the requirement for a voluntary decision.
52.Why should confidentiality be discussed before genetic testing?
Genetic results can carry implications for relatives as well as the person tested. Pretest discussion should address how results will be handled, who may access them, and what sharing the person authorizes. Family relevance creates an opportunity to support communication, but it does not erase confidentiality concerns. Legal duties and protections depend on the applicable setting; a general educational case should distinguish ethical communication planning from unsupported claims about universal disclosure rules.
Apply it
A patient wants testing but worries that relatives will automatically receive the report. Clarify the service's disclosure arrangements and the patient's preferences, then discuss ways the patient could communicate relevant familial information if appropriate.
Common pitfall: Do not promise absolute confidentiality under every circumstance or assume that family benefit automatically authorizes unrestricted disclosure; the actual consent and governing rules matter.
MedlinePlus Genetics: Informed consent · ABMGG General Exam: Blueprint and Content Codes
Genomics14%
53.When does a targeted assay differ from a sequencing panel?
A targeted assay can answer a narrow question about a known familial variant, while a multigene sequencing panel examines a selected set of genes relevant to a phenotype. Sanger sequencing and next-generation sequencing differ in throughput and implementation, but their clinical meaning still depends on the regions and variant classes assessed. Selecting a test requires matching the unresolved question to the assay's scope rather than assuming that the newest or largest platform always provides the most informative answer.
Apply it
A family has an established pathogenic sequence variant, and an adult relative wants to know whether it was inherited. A validated assay for that familial variant directly addresses the question without requiring an unrelated broad-panel search.
Common pitfall: A platform name does not specify complete coverage; a panel may omit a relevant gene or variant class, while a narrow assay can accurately answer its defined target.
MedlinePlus Genetics: Whole exome and whole genome sequencing · MedlinePlus Genetics: Interpreting genetic test results
54.How do exome and genome sequencing differ in scope?
Exome sequencing focuses primarily on protein-coding regions, while genome sequencing examines a much broader span of DNA, including noncoding regions. Broader sequence scope can address questions outside the exome, but it does not make every genomic mechanism equally detectable or interpretable. Coverage, analysis methods, and the types of variants reported remain important. A normal exome result therefore cannot be treated as evidence that every potentially relevant noncoding or other genomic change has been excluded.
Apply it
A patient has a plausible genetic disorder after nondiagnostic exome testing. Explain why a noncoding causal variant could remain unresolved and why considering genome sequencing requires reviewing the remaining biological question and the proposed laboratory analysis.
Common pitfall: Genome sequencing is not synonymous with complete diagnostic certainty; wider sequence acquisition does not automatically resolve all repeats, methylation changes, mosaicism, or uncertain variants.
MedlinePlus Genetics: Whole exome and whole genome sequencing · MedlinePlus Genetics: Interpreting genetic test results
55.What does a negative genetic test actually exclude?
A negative result means that the assay did not identify a reportable finding within its tested and interpretable scope. It can be highly informative when a known familial pathogenic variant is specifically absent, but less conclusive when the family's cause remains unknown. Residual explanations include untested genes, variant classes the assay detects poorly, and findings not yet interpretable. The report's methods and limitations therefore determine how strongly a negative result changes the proposed diagnosis.
Apply it
An unaffected relative tests negative for the family's confirmed pathogenic variant, while an affected proband has a negative broad panel without a known cause. Explain why these two negative results carry different implications for inherited risk.
Common pitfall: Do not convert an uninformative negative panel into proof of a nongenetic condition; absence of a detected cause differs from exclusion of all possible causes.
MedlinePlus Genetics: Interpreting genetic test results · NCI: Genetic Testing for Inherited Cancer Risk
56.How are sequence variants classified using combined evidence?
The 2015 ACMG/AMP framework defines pathogenic, likely pathogenic, uncertain significance, likely benign, and benign. In an explicitly hypothetical example, a validated disease-relevant functional assay satisfies PS3 at strong strength, and absence from adequately assessed controls satisfies the original PM2 at moderate strength. With independent observations and no conflicting evidence, one strong plus one moderate criterion meets a 2015 likely pathogenic combining rule. By contrast, PM2 plus PP3, a supporting computational criterion, does not meet that rule and can remain uncertain.
Apply it
Classify the hypothetical PS3-plus-PM2 example as likely pathogenic rather than pathogenic. Classify rarity plus computational prediction alone as insufficient for likely pathogenicity. This exercise uses the original 2015 criterion strengths; interpretation must identify the framework and specifications being applied.
Common pitfall: Several predictions do not supply several independent PP3 criteria. A predicted splice effect and the RNA observation used to establish that same effect must not automatically be counted as independent functional confirmations. Constitutional sequence rules are not interchangeable with somatic or copy-number classification systems.
Richards et al.: ACMG/AMP Standards and Guidelines for the Interpretation of Sequence Variants
57.When is an apparently de novo finding persuasive evidence?
A variant absent from both parents can support pathogenicity when the phenotype and gene–disease relationship fit, but the strength depends on what has been established. In the original 2015 ACMG/AMP framework, PS2 is strong de novo evidence with both maternity and paternity confirmed; PM6 is moderate evidence when parental relationships are assumed rather than confirmed. Adequate parental testing and a compatible family history remain necessary considerations. De novo occurrence alone does not classify every rare variant as pathogenic.
Apply it
A child has a highly concordant phenotype and a candidate variant absent from parental samples. Confirm whether both biological parental relationships are established before selecting PS2 rather than PM6. Confirming paternity alone is insufficient for PS2.
Common pitfall: A parent reported as clinically unaffected is not equivalent to a parent proven not to carry the variant; phenotype alone does not establish de novo status.
Richards et al.: ACMG/AMP Standards and Guidelines for the Interpretation of Sequence Variants
58.How can RNA studies strengthen variant interpretation?
RNA analysis can test whether a DNA variant changes splicing or transcript production, supplying direct evidence about a proposed molecular consequence. Its value depends on assay validation, appropriate controls, and expression of the relevant transcript in the sampled tissue. A result can support a mechanism without independently proving the entire clinical diagnosis. If the same underlying splicing observation informs several evidence descriptions, interpretation should avoid treating those descriptions as wholly independent confirmation.
Apply it
A candidate splice variant is studied in a tissue that expresses the disease-relevant transcript. Reproducible abnormal splicing absent from controls strengthens the proposed mechanism, while additional evidence is still needed to connect that mechanism to the patient's condition.
Common pitfall: A normal RNA result from a tissue that barely expresses the relevant transcript may be uninformative; technical absence of an abnormal product is not universal exclusion.
Richards et al.: ACMG/AMP Standards and Guidelines for the Interpretation of Sequence Variants
59.Which question does methylation testing answer?
Methylation testing evaluates epigenetic patterns rather than simply reading nucleotide sequence or counting copies. At a relevant imprinted region, an abnormal pattern can demonstrate disruption of the expected maternal and paternal contributions. However, different underlying events can produce a similar pattern, so follow-up studies may be needed to identify the cause and clarify recurrence implications. Test selection should distinguish establishing an imprinting abnormality from explaining the molecular event that produced it.
Apply it
A methylation assay detects only a maternal pattern at a region normally showing both parental patterns. Recognize an abnormal imprinting result, then use appropriate additional studies to distinguish loss of paternal material from other mechanisms.
Common pitfall: A methylation result is not a full sequence result or a complete parent-of-origin mechanism; do not infer a specific deletion solely from an abnormal imprinting pattern.
MedlinePlus Genetics: Genomic imprinting and uniparental disomy · ABMGG General Exam: Blueprint and Content Codes
60.How does segregation evidence depend on the disease model?
Segregation asks whether a variant tracks with a condition through a family in a way consistent with the proposed inheritance mechanism. Its meaning depends on penetrance, age at assessment, phenotype specificity, and whether relatives are genuinely informative. An unaffected young carrier may not contradict an adult-onset disorder, while an affected relative lacking the variant may challenge the proposed explanation. Family observations support interpretation only when evaluated against a coherent disease model.
Apply it
A candidate dominant variant occurs in affected adults and an unaffected child. Before calling this nonsegregation, determine whether the disorder usually appears later and whether the child's current age allows an informative phenotype assessment.
Common pitfall: Several relatives from one pedigree are not automatically independent proof of causation; shared inheritance, incomplete penetrance, and alternative diagnoses can complicate apparent cosegregation.
Richards et al.: ACMG/AMP Standards and Guidelines for the Interpretation of Sequence Variants · MedlinePlus Genetics: Reduced penetrance and variable expressivity
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Spend the largest share of study time on single gene inheritance: calculate transmission and conditional risks, distinguish penetrance from expressivity, and explain atypical inheritance mechanisms.
- Compare representative disorders by phenotype, gene mechanism, inheritance, and discriminating investigation. Practise the contrasts among FGFR3 skeletal dysplasias, FBN1-related multisystem findings, MYH7 cardiomyopathy, hearing-loss diagnoses, and developmental versus degenerative neurologic disease.
- For each genomic method, state its target, an informative use, and a major blind spot; compare sequence, dosage, chromosome architecture, RNA, and methylation evidence.
- Practise screening probability with explicit denominators, then connect positive prenatal and newborn screens to their appropriate diagnostic follow-up.
- Interpret cancer findings at the correct biological level: activating versus loss-of-function mechanisms, tumor versus constitutional status, parental inheritance versus de novo origin, and pathogenic variants versus uncertainty.
- Use the complete official outline to extend this selective guide into additional connective tissue, skeletal, cardiac, hematologic, neurogenetic, neurocutaneous, sensory, and metabolic disorders.
A practical preparation plan
1. Map the full outline
Create an 11-domain study map from the official effective-August-2025 blueprint. Place these 60 concepts under it, then mark unrepresented subtopics for additional study. Allocate time approximately by the published weights rather than giving every domain equal time.
2. Calculate inheritance before interpreting phenotype
Draw parental genotypes and list possible transmissions. State whether the question concerns all pregnancies, a known son or daughter, an unaffected sibling, or phenotype by a specified age. Add penetrance only after calculating transmission.
3. Choose tests by the unresolved mechanism
For each case, decide whether the question concerns sequence, copy number, chromosome arrangement, repeat instability, tissue mosaicism, transcript effects, or imprinting. Explain why the selected method answers that question and why a tempting alternative may miss it.
4. Build an evidence argument
Separate a variant's observed consequence from its disease classification. Examine gene–disease mechanism, phase, de novo status, segregation, functional evidence, and phenotype fit. Apply named criterion strengths and combining rules without counting the same observation twice.
5. Complete the independent drills
Answer all 20 questions before reading explanations. For each error, write the decisive cue and explain why each alternative fails. Use the flashcards to recall mechanisms rather than memorize the question wording or option positions.
6. Extend clinical comparisons
For each disorder group in the official outline, build additional comparisons using presenting features, disease mechanism, inheritance, and the investigation that distinguishes close alternatives. Revisit any diagnosis that you can name but cannot explain mechanistically.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ACMG: Career Opportunities
- ABMGG: Content Outlines and Blueprints
- ABMGG General Exam: Blueprint and Content Codes
- ABMGG: Testing Process
- ABMGG official homepage
- NHGRI: Meiosis
- NHGRI: Crossing Over
- MedlinePlus Genetics: What kinds of gene variants are possible?
- CDC Stacks: Supplementary Material—Hardy-Weinberg Equilibrium
- Miller et al.: Consensus statement on chromosomal microarray
- MedlinePlus Genetics: Changes in chromosome number
- MedlinePlus Genetics: Changes in chromosome structure
- NHGRI: Fluorescence In Situ Hybridization
- MedlinePlus Genetics: Inheritance patterns
- MedlinePlus Genetics: Chances of inheriting a genetic condition
- MedlinePlus Genetics: Reduced penetrance and variable expressivity
- MedlinePlus Genetics: Genomic imprinting and uniparental disomy
- MedlinePlus Genetics: Anticipation
- MedlinePlus Genetics: Tay-Sachs disease
- MedlinePlus Genetics: Glucose-6-phosphate dehydrogenase deficiency
- SMFM Consult Series #74: Cell-free DNA screening for aneuploidies—Updated guidance
- MedlinePlus Genetics: Informed consent
- NCI: BRCA Gene Changes—Cancer Risk and Genetic Testing
- NCI: Genetic Testing for Inherited Cancer Risk
- Richards et al.: ACMG/AMP Standards and Guidelines for the Interpretation of Sequence Variants
- MedlinePlus Genetics: Whole exome and whole genome sequencing
- NHGRI: Genetic Drift
- NHGRI: Genetic Testing Report—Glossary
- MedlinePlus Genetics: Gene variants and their origins
- MedlinePlus Genetics: X chromosome
- MedlinePlus Genetics: Heritability
- MedlinePlus Genetics: Interpreting genetic test results
- HRSA: Newborn Screening Results and Follow-Up
- NHGRI: Oncogene
- NHGRI: Tumor Suppressor Gene
- Bulletin-of-Information-2026-New-Deadlines-Update.pdf
- Founder Effect
- Preimplantation Genetic Testing | ACOG - College
- 36049896.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.